Clinical Trials · NCT05827081
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 1,464
- Start date
- Feb 2024
- Locations
- 214 sites, 16 countries
- Primary endpoint
- Invasive Breast Cancer Free Survival (iBCFS) rate at 3 years